To validate SensiScreen® assays in the clinical setting, we used SensiScreen® to retrospectively analyse FFPE DNA from three different patient populations with histologically confirmed CRC that were previously analysed by common KRAS mutation tests. This evidence concerns the gene KRAS and colorectal carcinoma.